Forbion raises record €2.3 billion to back 30 European biotech firms
Forbion Capital Partners announced it has closed two new funds, the Growth Opportunities Fund IV and Ventures Fund VIII, together raising €2.3 billion, a record for the European life‑sciences venture firm.
The capital will be deployed to support roughly 30 biotech companies that the firm describes as “high potential,” with several investments already completed.
Investors in the round include pharmaceutical giant Eli Lilly, German VC KfW Capital and the U.S. nonprofit Kauffman Foundation, reflecting strong demand for life‑science funding.
Managing partner Sander Slootweg said the sizable dry‑powder position will allow Forbion to select and scale companies developing paradigm‑shifting treatments for unmet medical needs.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 ‘high potential’ biotechs”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that